Key Updates on the Return of Ranitidine

Key Updates on the Return of Ranitidine

SKU: CEI-KEY-UPDATES–1768712400-PODCAS-PH-9782
24.00 USD In stock Buy at Merchant

This course discusses the FDA’s re-approval of ranitidine, focusing on the reformulated product’s changes and practical considerations for pharmacists.

  • The description claims that ranitidine was withdrawn from the market over safety concerns but was recently re-approved by the FDA.
Specifications
Duration
30m
CEUs
0.05
Target Role
Pharmacist

AI Readiness

Good foundation, but some important product data is still missing.

75%
3 important fields missing Claim to view full AI report
Data sourced from www.ceimpact.com. Last updated: The description was auto-generated by an AI model based on the merchant's description. It may not be accurate or complete.
Claim www.ceimpact.com to see AI Product Health

Takes ~2 minutes. No storefront changes.